Oruka Therapeutics, Inc.

NasdaqGM:ORKA Stock Report

Market Cap: US$4.4b

Oruka Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGM:ORKA Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
15 Jun 26SellUS$51,083Paul QuinlanIndividual733US$69.69
15 Jun 26SellUS$41,814Laura SandlerIndividual600US$69.69
15 Jun 26SellUS$120,494Lawrence KleinIndividual1,729US$69.69
16 Mar 26SellUS$16,314Arjun AgarwalIndividual395US$41.30
16 Mar 26SellUS$71,408Lawrence KleinIndividual1,729US$41.30
16 Mar 26SellUS$30,273Paul QuinlanIndividual733US$41.30
16 Mar 26SellUS$26,473Joana GoncalvesIndividual641US$41.30
16 Mar 26SellUS$24,780Laura SandlerIndividual600US$41.30
17 Sep 25BuyUS$5,000,100Fairmount Funds Management LLCCompany333,340US$15.00

Insider Trading Volume

Insider Buying: ORKA insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of ORKA?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders1,373,7662.28%
Hedge Funds3,705,2626.14%
VC/PE Firms4,148,4286.88%
General Public6,459,50310.7%
Institutions44,625,14274%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 61.1%.

Top Shareholders

Top 25 shareholders own 73.19% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
12.3%
FMR LLC
7,431,403US$537.6m2.34%0.02%
6.88%
VR Management, LLC
4,148,428US$300.1m0%8.96%
6.14%
Fairmount Funds Management LLC
3,705,262US$268.0m0%12.28%
5.85%
BlackRock, Inc.
3,527,087US$255.1m-0.35%no data
4.42%
Viking Global Investors LP
2,666,690US$192.9m0%0.49%
3.85%
Paradigm Biocapital Advisors LP
2,320,316US$167.9m35.7%3.56%
3.41%
RTW Investments, LP
2,058,148US$148.9m0%1.36%
3.37%
Deep Track Capital, LP
2,034,203US$147.2m-5.89%2.45%
3.08%
Vanguard Capital Management, LLC
1,859,631US$134.5m0%no data
2.68%
State Street Global Advisors, Inc.
1,613,461US$116.7m16.6%no data
2.6%
Remedium Capital Partners, LLC
1,565,661US$113.3m0.85%30.24%
2.31%
Perceptive Advisors LLC
1,395,501US$101.0m-5.49%2.0%
1.74%
Polar Capital Holdings Plc
1,047,693US$75.8m7.09%0.15%
1.67%
Citadel Advisors LLC
1,007,537US$72.9m38.8%0.05%
1.66%
Franklin Resources, Inc.
999,763US$72.3m6.54%0.02%
1.58%
Geode Capital Management, LLC
954,867US$69.1m1.31%no data
1.53%
Lawrence Klein
925,580US$67.0m-0.19%no data
1.33%
Mercer Global Advisors Inc.
802,470US$58.1m7.67%0.08%
1.26%
Avidity Partners Management, L.P.
760,424US$55.0m15.1%10.87%
1.21%
T. Rowe Price Group, Inc.
727,449US$52.6m12%no data
0.95%
Woodline Partners LP
574,882US$41.6m0.06%0.14%
0.88%
Cormorant Asset Management, LP
533,340US$38.6m0%1.87%
0.84%
Bellevue Asset Management AG
507,008US$36.7m0%0.68%
0.83%
Affinity Asset Advisors, LLC
499,673US$36.1m-37.7%2.16%
0.79%
Synergy Asset Management, LLC
476,196US$34.4m3.76%3.27%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/19 15:01
End of Day Share Price 2026/06/18 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Oruka Therapeutics, Inc. is covered by 14 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Etzer DaroutBarclays
Julian HarrisonBTIG
Yatin SunejaGuggenheim Securities, LLC